Paper Details

  1. Home
  2. Paper Details

Psychosocial outcomes of repeated treatment of seizure clusters with midazolam nasal spray: Results of a phase 3, open-label extension trial.

Author: BrunnertMarcus, CamposRita, ChenLinda, FakhouryToufic, MengTze-Chiang, PullmanWilliam E, SzaflarskiJerzy P, Van EssPeter

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Midazolam nasal spray (MDZ-NS) was perceived favorably by patients and caregivers, with improvements in treatment satisfaction, reduced anxiety, and increased confidence about traveling.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To evaluate treatment satisfaction, level of anxiety, confidence about traveling with midazolam nasal spray (MDZ-NS), and health-related quality of life in patients with seizure clusters and their caregivers after repeated, intermittent use of MDZ-NS in the outpatient setting. METHODS: W...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.yebeh.2022.108989

データ提供：米国国立医学図書館（NLM）

Psychosocial Outcomes of Repeated Treatment of Seizure Clusters with Midazolam Nasal Spray: Results of a Phase 3, Open-Label Extension Trial

Imagine a camel caravan equipped with a special tool, like a water-carrying pouch, to address unexpected challenges. This research examines the psychosocial outcomes of using midazolam nasal spray (MDZ-NS) for repeated treatment of seizure clusters in patients with epilepsy. It explores the impact of MDZ-NS on treatment satisfaction, anxiety levels, confidence about traveling, and overall quality of life, similar to a caravan leader assessing the effectiveness of a new tool. This research provides valuable insights into the use of MDZ-NS as a treatment option for epilepsy.

Assessing the Effectiveness of MDZ-NS for Epilepsy

This study finds that repeated use of MDZ-NS for the treatment of seizure clusters is associated with improved treatment satisfaction, reduced anxiety, and increased confidence in patients and caregivers. This is like a caravan leader finding that the water-carrying pouch is reliable and effective in addressing the challenges of a long journey through the desert. This research provides valuable information for doctors and healthcare providers in managing seizure clusters in epilepsy patients.

Navigating the Desert of Epilepsy: Insights for Improved Quality of Life

This research underscores the importance of improving quality of life for individuals with epilepsy. By providing effective and readily available treatment options like MDZ-NS, healthcare professionals can help these individuals navigate the challenges of their condition and achieve a greater sense of independence and well-being. This study, like a caravan leader providing essential tools for a successful journey, helps patients with epilepsy navigate the complexities of their condition.

Dr. Camel's Conclusion

This study investigates the psychosocial outcomes of using midazolam nasal spray for the treatment of seizure clusters in epilepsy. Just like a camel caravan equipped with a water-carrying pouch, MDZ-NS provides valuable support for patients navigating the challenges of their condition. This research highlights the importance of understanding the psychosocial impact of treatment and seeking to improve the quality of life for individuals with epilepsy.

Date :
  1. Date Completed 2023-01-06
  2. Date Revised 2023-03-22
Further Info :

Pubmed ID

36410152

DOI: Digital Object Identifier

10.1016/j.yebeh.2022.108989

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.